In Brief
The role of de novo non-synonymous mutations in neuropsychiatric disorders is well established. In this study, Takata et al. explore the role of a different class of genetic variants, the synonymous mutations, and discover that they too contribute to autism and schizophrenia by affecting regulatory elements.
INTRODUCTION
Recent whole-exome sequencing (WESs) studies of family samples have pointed out the important role of de novo germline mutations in various genetically complex neuropsychiatric diseases, including autism spectrum disorders (ASDs) (Iossifov et al., 2012; Neale et al., 2012; O'Roak et al., 2012; Sanders et al., 2012) and schizophrenia (SCZ) Girard et al., 2011; Gulsuner et al., 2013; McCarthy et al., 2014; Xu et al., 2011 Xu et al., , 2012 .
These studies mainly focused on the impact of mutations on the protein coding properties. Although there is variation in their estimated contribution, analysis of collective data from these studies confirms a prominent enrichment of gene-disruptive de novo loss-of-function (LOF) mutations (i.e., nonsense, frameshift, and canonical splice site mutations) as well as a more moderate enrichment of de novo missense and inframe insertion/ deletion (indel) mutations in the cases, while there was no significant global enrichment of de novo synonymous mutations (Figure S1) . However, there is accumulating evidence that certain types of synonymous mutations have substantial contribution to complex human diseases, mediated by mechanisms other than changing protein sequences (reviewed in Sauna and Kimchi-Sarfaty, 2011) .
To test whether specific subsets of synonymous mutations contribute to the genetic architecture of ASD and SCZ, we comprehensively analyzed those de novo synonymous mutations with potential impact on five different types of gene regulatory function: splicing regulation, transcription factor binding, microRNA (miRNA) binding, codon optimality, and RNA secondary structure, by using publicly available WES datasets for ASD, SCZ, and control subjects (Table S1 ) as well as various bioinformatics tools and data sources (Figure 1 ). Subtypes of synonymous mutations that showed significant enrichment after correcting for multiple testing and genes hit by these mutations were further analyzed for their properties and relative contribution to the disease etiology.
near-splice site de novo synonymous mutations in ASD and SCZ, which has not been analyzed in the previous exome sequencing studies. We found that near-splice site de novo synonymous mutations are almost twice as frequent in ASD than controls (p = 0.00032, odds ratio [OR] = 1.96, 101 mutations in 1,043 ASD cases and 37 mutations in 731 controls, one-tailed 2 3 2 Fisher's exact test, Figure 2A ). Significant enrichment was also observed in SCZ (p = 0.023, OR = 1.53, 78 mutations in 1,021 SCZ cases and 37 mutations in 731 controls) and the combined case group (ASD+SCZ: p = 0.0012, OR = 1.74, 179 mutations in 2,064 ASD+SCZ cases and 37 mutations in 731 controls). De novo synonymous mutations that are distant from the nearest splice site (i.e., distance to the nearest splice site > 30 bp) were not enriched ( Figure 2A ). These results suggest that, first, like the cancer study (Supek et al., 2014) , only the Published WES studies (ASD Iossifov et al., 2012; Neale et al., 2012; O'Roak et al., 2012; Sanders et al., 2012] , SCZ Girard et al., 2011; Gulsuner et al., 2013; McCarthy et al., 2014; Xu et al., 2011 Xu et al., , 2012 , and control subjects [Gulsuner et al., 2013; Iossifov et al., 2012; O'Roak et al., 2012; Rauch et al., 2012; Sanders et al., 2012; Xu et al., 2012] ) were used to assess enrichment of synonymous mutations likely to affect genetic regulatory elements in the case groups using Fisher's exact tests (one-tailed). The potential impact of each de novo synonymous mutation on five different types of genetic regulatory functions (splicing regulation, transcription factor [TF] binding, miRNA binding, codon optimality, and mRNA secondary structure) was evaluated using various bioinformatics tools and data sources (see Supplemental Experimental Procedures). After performing exploratory enrichment analyses, we applied correction for multiple testing (Benjamini-Hochberg procedure) for the number of hypotheses tested to identify subtypes of potentially ''functional'' synonymous mutations robustly enriched in the case groups and were further analyzed for gene intolerance against functional mutations, functional gene-set enrichment, recurrence of damaging mutations (gene-based analysis), and relative contribution to the disease liability (mutation-based analysis). DHS, DNase I hypersensitive sites.
near-splice site de novo synonymous mutations are enriched among cases. Second, this enrichment cannot be explained by the potential biases due to combination of the data from multiple studies (see Supplemental Information and Figure S2 ). When comparing the cumulative distributions of all de novo synonymous mutations according to their distance to the nearest splicing site between cases and controls, there is an overall significant difference for ASD (p = 0.0023, two-sample Kolmogorov-Smirnov test), SCZ (p = 0.019) and ASD+SCZ (p = 0.0018) ( Figure 2B ). In agreement with Supek and colleagues, the difference in cumulative distributions between cases and controls was maximized for mutations within $30 bp from the nearest splice site ( Figure 2B , inset).
Next, we analyzed which of the individual mutations are more likely to affect splicing by referring to exonic splicing regulator (ESR) hexamer sequences (Ke et al., 2011) , the RESCUE-ESE server (Fairbrother et al., 2002) , and the FAS-ESS server (Wang et al., 2004 Figure 2C ) and there was no enrichment of near-splice site mutations that do not change ESR ( Figure 2C ). . Using the single integrated dataset generated by combining the data of 125 cell types , we analyzed whether de novo synonymous mutations in ASD and SCZ are preferentially found in DHS and found no significant enrichment of de novo synonymous mutations within these DHS in any of the case groups as compared to the controls (Figure 3 ). We then refined our analysis based on the data derived from normal brain tissues in the ENCODE Experiment Matrix (https://genome. ucsc.edu/ENCODE/dataMatrix/encodeDataMatrixHuman.html). Three such available datasets were used originally, two derived from frontal cortex tissues (ENCODE Common Cell Types ID: ''Cerebrum_frontal_OC'' and ''Frontal_cortex_OC'') and one derived from cerebellum tissues (ENCODE ID: ''Cerebellum_ OC''). With the DHS identified in the Cerebrum_frontal_OC data there was significant enrichment of de novo synonymous In addition, we observed significant enrichment of synonymous mutations within fetal brain-derived DNase I footprints (Neph et al., 2012) , which indicate precise genomic locations bound by regulatory factors (Kavanagh et al., 2013) (p = 0.012 and 0.039, respectively, see Supplemental Information for details), further supporting a role of synonymous mutations affecting TF binding affinity in SCZ.
Enrichment of De
In contrast, when we evaluated whether synonymous mutations likely affecting miRNA binding sites in the coding regions (we could not include mutations in 3 0 UTR, the main targets of miRNAs), codon optimality, or RNA secondary structure are enriched in case subjects, we did not observe strong enrichment considering the number of hypotheses tested in our study (Figure S3 , see Supplemental Information for details).
After these exploratory analyses, we applied multiple testing correction (Benjamini-Hochberg procedure) for the number of all hypotheses tested (87 in total, Table S2 ) and found that enrichment of near-splice site synonymous mutations, especially those changing ESR, in ASD (p corrected = 0.003) and enrichment of synonymous mutations within the frontal cortex-derived DHS (Cerebrum_frontal_OC) in SCZ (p corrected = 0.017) remain statistically significant (Table S2) . Enrichment of these types of synonymous mutations was confirmed by a permutation-based analysis and supported by analyses using independent datasets including the data of DHS from the Roadmap Epigenomics Project (Kundaje et al., 2015) 
Confirmation of Enrichment of De Novo Near-Splice Site Synonymous Mutations Changing ESR in ASD by a Joint Analysis Using New Large-Scale Datasets
In addition to the analyses described thus far, where we examined 253 mutations in 1,043 ASD probands, 228 mutations in 1,021 SCZ probands, and 154 mutations in 731 controls, we conducted a joint analysis by incorporating two additional large-scale WES datasets for ASD that were published later (De Rubeis et al., 2014; Iossifov et al., 2014) to test whether enrichment of de novo near-splice site synonymous mutations changing ESR persists in the combined dataset that comprises 1,562 synonymous mutations (1,046 in ASD subjects and 516 in controls). In SCZ, no new datasets were available for comparison. Near-splice site synonymous mutations changing ESR remained significantly enriched in the overall combined dataset that is three to four times larger than the initial dataset (p = 0.00049, OR = 1.55, 273 mutations in ASD and 96 mutations in controls, one-tailed Fisher's exact test, see also Supplemental Experimental Procedures). The observed OR in the joint analyses was lower than the one observed in our initial analyses (1.55 versus 2.52). This could be partly explained by phenotypic heterogeneity among the datasets used in the joint analyses (e.g., more non-sporadic probands [De Rubeis et al., 2014] and more moderately severe cases, such as ASD males without ID [Iossifov et al., 2014] , in the newer datasets). Furthermore, this may also, in part, be a manifestation of the ''winner's curse,'' the upward bias in the estimated effect of a newly identified risk variant, often observed in genetic association studies (Kraft, 2008) . Regardless, confirmation of our findings warrants further large-scale studies in independent and well-phenotyped cohorts to further confirm enrichment of these mutations in ASD and to estimate their effect size. The same is true for our finding in SCZ, given the small number of synonymous mutations within frontal-cortex derived DHS analyzed in this study (50, 38, and 14 in SCZ, ASD and controls, respectively) .
Genes Hit by Potentially ''Functional'' Synonymous Mutations in ASD Are Involved in Synaptic and Neuronal Functions We tested whether genes hit by these potentially ''functional'' de novo synonymous mutations are more likely to be among those intolerant to functional genetic variation as defined by the Residual Variation Intolerance Score (RVIS) (Petrovski et al., 2013) and saw significant enrichment of the ''intolerant'' genes (see Supplemental Experimental Procedures for the definition of these genes) among both genes with near-splice site synonymous mutations changing ESR in ASD (p = 0.030, binominal exact test) and genes with synonymous mutations within the frontal cortex-derived DHS in SCZ (p = 0.012) ( Figure S5 ). By contrast, there was no enrichment in the control gene sets, which are the genes with near-splice site synonymous mutations not changing ESR or mutations distant from the splice site in ASD and genes outside the frontal cortex-derived DHS in SCZ.
With functional gene-set enrichment analyses using the ToppGene Suite (Chen et al., 2009) , there was significant enrichment of genes related to calcium channels and transporters (e.g., ''GO: Molecular Function; voltage-gated calcium channel activity,'' Benjamini-Hochberg corrected p value [p BH ] = 0.0062 and . Enrichment of these terms as well as synaptic genes was not observed among genes with de novo synonymous mutations distant from the nearest splice site (>30 bp) or near-splice site mutations not changing ESR in ASD (171 genes) and genes with synonymous mutations changing ESR in controls (23 genes) (Table S3) .
In contrast, when we used the genes with de novo synonymous mutations within the frontal cortex-derived DHS in SCZ (60 genes) as input, there was no term significantly enriched after performing Benjamini-Hochberg correction (p BH < 0.05, Table  S3 ). This may suggest that the pathways affected by these genes in SCZ are more heterogeneous and the number of the input genes was too small to identify enrichment of particular biological pathways.
Significant Contribution of Potentially Functional De Novo Synonymous Mutations to Disease Liability
We examined the relative contribution of functional synonymous mutations to variability on the liability scale as compared to other mutation types and estimate that near-splice site synonymous mutations changing ESR in ASD and synonymous mutations within the frontal cortex-derived DHS in SCZ can explain 1.5% and 0.6% of the variability on the liability scale, respectively (Table S4 , see Supplemental Experimental Procedures for details). These estimated contributions are comparable to that of de novo LOF mutations (1.3% for ASD and 0.74% for SCZ) and much higher than that of de novo missense mutations (0.1% for both ASD and SCZ). It is also notable that the per-individual mutation rates and relative risks compared to controls for potentially functional synonymous mutations are similar to or not greatly different from those for LOF mutations (Table S4) .
Candidate ASD and SCZ Genes that Are Recurrently Hit by Damaging De Novo Mutations Including Potentially Functional Synonymous Mutations
Identification of these potentially functional de novo synonymous mutations can help discover new genes involved in disease, as genes with recurrent functional de novo mutations including LOF, damaging missense, and now ''functional'' synonymous mutations are more likely to be associated with disease. We evaluated the statistical significance of observing multiple functional de novo mutations, including potentially functional synonymous mutations in the same gene, by applying a framework for the interpretation of de novo mutations , which takes into consideration gene length and local sequence context. Among the genes hit by near-splice site synonymous mutations changing ESR in ASD, eight are hit by other functional de novo mutations in ASD (Table 1) . Of these, RAB2A, in which a LOF mutation was previously reported (Sanders et al., 2012) , showed the highest significance (p = 4.48 3 10 À6 ). The p value for this gene is close to the genome-wide significance threshold (p = 2.74 3 10 À6 ) considering the number of genes tested (n = 18,271) , and the corresponding p value conservatively corrected for the number of tested genes is 0.081. Among the genes identified in this study in SCZ, seven genes are hit by additional functional mutations in SCZ (Table 1) . It is notable that one potentially functional synonymous mutation was identified in the SETD1A gene, in which two LOF mutations were previously reported in SCZ (Takata et al., 2014) . This gene harbors significantly more functional mutations than expected after performing genome-wide correction (p raw = 1.79 3 10 À6 , p corrected = 0.033). In addition, another SCZ patient with a de novo LOF mutation in this gene was identified in a recent study (Guipponi et al., 2014) . In total there are three de novo LOF and one de novo functional synonymous mutations in SETD1A among 1,074 probands, and the corresponding p value is 1.2 3 10 À8 , further demonstrating that this gene is very likely to be a genuine disease susceptibility gene. In addition, both SETD1A and RAB2A were among the highly intolerant genes in the human genome in a recent variation analysis of over 60,000 humans in ExAC (http://biorxiv.org/content/ early/2015/10/30/030338), (probability of being LOF intolerant, pLI = 0.999 for SETD1A and 0.971 for RAB2A), indicating that LOF variants within these genes are under natural selection in the human genome.
DISCUSSION
Our analyses found significant enrichment among cases of nearsplice site mutations changing ESR in ASD and of synonymous mutations within frontal-cortex derived DHS in SCZ. The finding in ASD was confirmed in subsequent analyses that integrated the initial dataset with additional, newly published, large datasets (De Rubeis et al., 2014; Iossifov et al., 2014) . Biologically interpretable results in our exploration of the properties of genes hit by these potentially ''functional'' synonymous mutations further support contribution of these mutations to disease etiology. Through analyzing genes hit by potentially functional synonymous mutations using gene intolerance scores, we found a pattern similar to de novo LOF and missense mutations reported in earlier studies. We also saw enrichment of genes related to brain function and biological processes previously implicated in the disease (e.g., calcium channels and Wnt/beta-catenin signaling for ASD). Notably, near-splice site synonymous mutations, especially those changing ESR, have been shown to be significantly enriched in patients with epileptic encephalopathies (Allen et al., 2013) , indicating they may contribute to other neuropsychiatric disorders ( Figure S6 , see Supplemental Information for details). By evaluating genes hit by multiple de novo damaging mutations, including potentially functional synonymous mutations, we identified RAB2A and SETD1A as promising candidate genes for ASD and SCZ, respectively. These results are particularly important for development of valid animal and cellular disease models, an essential step toward clinical translation . RAB2A encodes a small guanosine triphosphatase (GTPase) protein that is required for protein transport from the endoplasmic reticulum (ER) to the Golgi complex (Tisdale et al., 1992) . Association between common SNPs in this gene and the density of calbindin-positive GABAergic neurons in postmortem prefrontal cortex was reported in a GWAS (Kim and Webster, 2011) , suggesting a role of RAB2A in prefrontal inhibitory neural circuits. In addition, a RAB2A polymorphism was recently shown to impact prefrontal cortical morphology, functional connectivity, and working memory (Li et al., 2015) , all key deficits implicated in the etiology of neurodevelopmental disorders, including SCZ and ASD (Schubert et al., 2015) . In addition, RAB2A is a target of CHD8, a well-established ASD gene involved in prenatal human neurodevelopment (Cotney et al., 2015) .
SETD1A, in which three de novo LOF mutations were previously reported (Guipponi et al., 2014; Takata et al., 2014) , encodes a catalytic unit of the histone H3 lysine 4 (H3K4) methyltransferase complex. Identification of an additional potentially functional de novo synonymous mutation in this gene and the accumulating evidence for involvement of the chromatin regulation pathway in neuropsychiatric diseases, including ASD and SCZ, further supports that SETD1A is a genuine susceptibility gene for SCZ. Notably, strong association of LOF mutations in SETD1A (also known as KMT2F) with SCZ was confirmed by a recent large-scale study examining several tens of thousands of WES data (Singh et al., 2016) .
The estimated proportion of disease liability explained by these mutations is comparable to de novo LOF mutations and suggests that potentially functional synonymous mutations can contribute to the disease risk as much as LOF mutations. Although the overall contribution of potentially functional synonymous mutations to disease liability may not be very large ($1%) because these mutations are very rare, it should be noted that each mutation could greatly increase the disease risk. Indeed, ORs observed for potentially functional synonymous mutations are comparable to those observed for de novo LOF mutations (see Figures 2 and S1 ). Furthermore, genetic regulatory elements are spread throughout the genome. While the datasets used in our analyses cover only the coding regions that comprise $1% of the human genome, it is likely that mutations affecting regulatory elements outside the coding regions can explain a substantial part of disease liability. Detailed investigation of the impact of mutations on regulatory elements both inside and outside the coding regions, using whole-genome or ''regulome'' sequencing along with the rapidly increasing knowledge on various types of functional DNA elements in the human genome (ENCODE Project Consortium, 2012), will help us better understand the genetic architecture of complex neuropsychiatric diseases. 
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